On August 15, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), completed a sale of 5,583 shares of the company’s stock. The transaction was filed on August 16, 2024, as reported in the SEC filing. Following this transaction, the insider now owns 200,710 shares of Natera Inc.

Natera Inc. specializes in genetic testing and diagnostics, with a focus on prenatal, oncology and organ transplant testing. The company’s goal is to provide detailed genetic information to support medical decisions and patient care.

The shares were sold at a price of $118.91, for a transaction value of approximately $664,026.53. This sale adds to the total of 254,911 shares sold by Steven Chapman over the past year, with no purchases recorded during the same period.

Natera Inc.’s insider transaction history shows a trend towards insider selling, with 100 insider sales and no insider purchases in the last year. This transaction pattern provides insight into insider sentiment towards the stock in the context of its current market performance.

At the time of the last sale, Natera Inc had a market capitalization of about $15.334 billion. The stock’s valuation metrics show a GF Value of $72.47, which translates to a Price to GF Value ratio of 1.64. This suggests that Natera Inc is significantly overvalued according to GuruFocus’ intrinsic value, which takes into account historical trading multiples, an adjustment factor based on past performance, and future business projections.

Valuation analysis highlights the stock’s current premium compared to its GF value and may influence the insider’s decision to reduce their holdings at that price level.

For more detailed information on Natera Inc.’s financial metrics, such as price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow ratio, investors and analysts can visit the detailed stock analysis pages on GuruFocus.

This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.

This article first appeared on GuruFocus.